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The impact of poor asthma control among asthma patients
treated with inhaled corticosteroids plus long-acting β2-
agonists in the United Kingdom: a cross-sectional analysis
Ian D. Pavord1, Nicola Mathieson2, Anna Scowcroft2, Riccardo Pedersini3,4, Gina Isherwood3 and David Price 5
There are several new treatment options for patients whose asthma remains uncontrolled on free-dose and ﬁxed-dose
combinations of inhaled corticosteroids plus long-acting β2-agonists (ICS+LABA). In order to evaluate the likely impact of these
treatments, we assessed the effect of uncontrolled asthma on healthcare and patient burden within the UK among adult patients
treated with ICS+LABA. Data obtained from 2010–2011 UK National Health and Wellness Surveys identiﬁed 701 patients treated
with ICS+LABA. Patients with not well-controlled asthma (Asthma Control Test™ score <20) were compared with well-controlled
asthma (score≥ 20) patients on multiple measures. Cost burden was calculated using healthcare resource utilisation models and
work productivity and impairment questionnaire. Overall, 452 and 249 patients reported not well-controlled and well-controlled
asthma, respectively. A greater proportion of not well-controlled patients visited the accident & emergency department (21 vs. 14%,
P = 0.016), were hospitalised (13 vs. 8%, P = 0.022) and had lower mental and physical health-related quality of life (P < 0.001) and
impaired work productivity and activity scores: presenteeism (23 vs. 11%, P < 0.001), work impairment (29 vs. 17%, P < 0.001) and
activity impairment (46 vs. 24%, P < 0.001). Calculated direct and indirect yearly costs/person doubled among not well-controlled
compared to well-controlled asthma patients (£6592 vs. £3220). Total cost to society was estimated at £6172 million/year (direct
costs, £1307 million; indirect costs, £4865 million). In conclusion, not well-controlled asthma is common among UK adults treated
with ICS+LABA, resulting in impairments across a number of important health outcomes and represents a signiﬁcant unmet need
and resource burden.
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INTRODUCTION
International strategies set forth by the Global Initiative for Asthma
(GINA), as well as UK-speciﬁc recommendations and guidelines help
in effective clinical management.1, 2 Inhaled corticosteroids (ICS) are
the ﬁrst choice agent for patients requiring regular maintenance
treatment.3 Despite the presence of established treatment guide-
lines, many asthma patients still experience persistent symptoms
and, therefore, poor disease control.4
For patients who experience persistent symptoms or exacerba-
tions, guidelines advise the stepwise use of higher doses of ICS
and/or the use of additional adjunct therapies such as long-acting
β2-agonists (LABAs).
1 ICS and LABA ﬁxed-dose combinations are
widely used and have been estimated to account for approxi-
mately 54% of all ICS prescribed in the UK and represent 80% of
ICS prescribing costs.5
When asthma is not well-controlled, patients generally experi-
ence functional limitations and are at an increased risk of
exacerbations, pulmonary function loss and mortality resulting in
signiﬁcant direct and indirect resource costs.6–9 New treatment
options, including tiotropium and biological agents, are available
to treat these patients.10 A clear understanding of these costs is
important in order to assess the impact of these therapies.
Several studies looking at direct costs have been conducted in
the UK: a study of over 12,000 patients found that poorly
controlled asthma increased the risk of exacerbations and
the need for emergency medical attention, which was in turn
associated with a three-fold to four-fold increase in care costs.11, 12
A 2013 study estimated the total direct cost of treating asthma in
the UK to be over £750 million, with the individuals with
uncontrolled asthma and multiple exacerbations (~ 2.7%) account-
ing for nearly £53 million of care costs (~ 7%).13
Indirect costs associated with poorly controlled asthma are also
recognised to be signiﬁcant.14 They can include costs arising from
impaired work and education, productivity and absenteeism,
transportation to and from medical visits, and impairments in
quality of life.15–18 European studies have reported signiﬁcant
indirect costs of up to €1800 per trimester in Spanish patients with
not well-controlled asthma,19 underscoring the importance of
effectively addressing inadequate control.20
Despite an increasing body of real-world evidence demonstrat-
ing a link between control of asthma symptoms and the
associated burden,21–23 there remains a paucity of data on the
burden of uncontrolled asthma on patients treated speciﬁcally
with ICS and LABA combinations. An enhanced understanding of
the direct and indirect costs associated with asthma control
among this patient group is needed to better inform treatment
guidelines and scientiﬁc research. This study aimed to investigate
the impact of uncontrolled asthma among adult patients treated
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with ICS+LABA on healthcare resource and patient burden based
on data obtained from the 2010 and 2011 UK National Health and
Wellness Surveys (NHWS).
RESULTS
Descriptive analyses
The combined 2010–2011 NHWS sample of the UK adult
respondents self-reporting a physician diagnosis of asthma (N =
3105) projected to the overall 2011 UK adult population yielded an
estimate of 5,088,605 asthma patients, corresponding to 10.4% of
the adult population (Supplementary Table 1 provides additional
information on age and gender). This estimate was higher than the
Quality and Outcomes Framework ﬁgures,24 although its 5.9%
prevalence of asthma for 2011–2012 in the UK was derived from
data that were not weighted by age and gender. Among the
3105 surveyed asthma respondents (Supplementary Table 2),
almost 30% reported currently being treated with ICS and LABA
in free-dose combination or ﬁxed-dose combination (ICS+LABA). Of
these, approximately 20% self-reported a concomitant physician
diagnosis of chronic obstructive pulmonary disease (COPD), chronic
bronchitis or emphysema (n = 880, projected to 1,430,634) and
were therefore excluded from further analyses. The remaining 80%
(n = 701, projected to 1,142,033) were divided into two groups
according to the Asthma Control Test (ACT) score: 36% (n = 249,
projected to 402,293) had well-controlled asthma and 64% (n = 452,
projected to 739,740) had not well-controlled asthma.
Bivariate analyses
Tables 1–4 describe the personal characteristics, health outcomes,
asthma characteristics and adherence of those with well-controlled
and not well-controlled asthma. Not well-controlled asthma
patients tended to have lower income (48 vs. 31% earn less than
£20,000), lower levels of employment (42 vs. 53%) and a greater
proportion of obesity (38 vs. 25%), while well-controlled asthma
patients were more likely to be overweight (42 vs. 31%; Table 1).
A greater proportion of not well-controlled asthma patients
visited the Accident & Emergency (A&E) (21 vs. 14%) or were
hospitalised (13 vs. 8%) in the previous 6 months, saw their
general practitioner (GP) or specialist more often (8 vs. 5 times in
previous 6 months), talked to their doctor about their asthma
more often (on average 3 vs. 1 time over the past 12 months) and
had more severe asthma symptoms regardless of whether they
were taking their asthma medication or not (Tables 2 and 3). These
healthcare visits were not necessarily asthma related, but could be
due to any cause. The health-related quality of life (HRQoL) of not
well-controlled asthma patients was lower on all three summary
scores of the Short Form Survey Instrument (SF-12v2) (mental
component summary [MCS]: 43 vs. 47; physical component
summary [PCS]: 40 vs. 48; health utility: 0.65 vs. 0.74), while their
Table 1. Comparison of asthma respondents with well-controlled and not well-controlled asthma treated with ICS+LABA without concurrent
diagnosis of COPD, chronic bronchitis, or emphysema: personal characteristics
ICS+LABA (free and ﬁxed-dose combination)
No COPD diagnosis Not well-controlled Well-controlled Total Test
n Index n Index n Index P
Gender 0.263
Female 288 63.7% 148 59.4% 436 62.2%
Age, years 0.812
n, mean 452 48.9 249 48.6 701 48.8
Married or living with partner 0.242
No 317 70.1% 185 74.3% 502 71.6%
Education 0.056
Less than university graduate 232 51.3% 109 43.8% 341 48.6%
Annual household income <0.001
Less than £10,000 73 16.2% 27 10.8% 100 14.3%
£10,000 to £19,999 142 31.4% 50 20.1% 192 27.4%
£20,000 to £49,999 163 36.1% 105 42.2% 268 38.2%
£50,000 or more 30 6.6% 34 13.7% 64 9.1%
Declined to answer 44 9.7% 33 13.3% 77 11.0%
Employment status 0.004
Not employed 263 58.2% 117 47.0% 380 54.2%
BMI, kg/m2 0.002
Underweight or normal range (BMI< 25) 118 26.1% 66 26.5% 184 26.2%
Overweight (25≤ BMI< 30) 138 30.5% 105 42.2% 243 34.7%
Obese (BMI≥ 30) 171 37.8% 62 24.9% 233 33.2%
Declined to answer 25 5.5% 16 6.4% 41 5.9%
Smoking behaviour <0.001
Not smoking 367 81.2% 229 92.0% 596 85.0%
Charlson Comorbidity Index 0.273
n, mean 452 0.31 249 0.25 701 0.29
Sample size 452 249 701
BMI body mass index, COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroids, LABA long-acting β2-agonist
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work and activity impairments were greater: presenteeism
(23 vs. 11%), overall work impairment (29 vs. 17%) and activity
impairment (46 vs. 24%).
There was no difference in reported adherence using the
Morisky Medication Adherence Scale (MMAS-4; Table 4), suggest-
ing that their diminished asthma control may be due to other
reasons such as incorrect choice of inhaler, poor inhalation
technique, smoking, comorbidity25 or worsening of their condi-
tion. When considering the individual adherence questions within
the MMAS-4, a greater proportion of not well-controlled asthma
patients reported stopping taking medications when they felt
better (27 vs. 19%).
Multivariate analyses
Health-related quality of life (SF-12v2). Not well-controlled asthma
patients had worse HRQoL compared with well-controlled patients
on all three metrics (MCS, PCS and health utility; Supplementary
Table 3a). It also appears that MCS scores improved with age and
decreased in people who smoked and among people with more
comorbidities as measured by the Charlson Comorbidity Index
(CCI). PCS scores, on the other hand, decreased with age, as well as
with obesity and CCI. Finally, health utility was lower in males,
obese respondents, smokers and those with more comorbidities.
All effects were signiﬁcant (Supplementary Table 3).
Adherence (MMAS-4). In terms of individual MMAS questions,
patients with well-controlled asthma were less likely to stop taking
medications when they felt better, while the overall MMAS score
did not show any signiﬁcant difference between both sets of
patients. Instead, adherence (overall MMAS score) seemed to be
affected by gender, age and income (Supplementary Table 3b):
males had a lower likelihood of being non-adherent, and being
older and having a higher income were associated with a higher
likelihood of being non-adherent.
Use of healthcare resources. Supplementary Table 4a shows that
use of healthcare resources was signiﬁcantly higher among
patients with poorly controlled asthma (number of visits to GP,
specialist, A&E and hospital), and increased with comorbidities
(CCI). In addition, adherence to prescribed asthma medication was
associated with signiﬁcantly more specialist and A&E visits,
suggesting that patients with more severe asthma may be more
adherent to their asthma medications.
Work productivity loss (Work productivity and activity impairment
[WPAI]). Absenteeism, presenteeism, overall work impairment
and activity impairment were all higher in not well-controlled
asthma patients compared to those with well-controlled asthma
(Supplementary Table 4b). When combined, all scores were lower
among males; absenteeism decreased with adherence; higher
annual household income was associated with higher absentee-
ism, overall work impairment and activity impairment; age and
non-adherence were positively associated with absenteeism and
higher body mass index was associated with higher absenteeism
and presenteeism.
Cost analysis. Supplementary Table 5 and Table 5 summarise the
yearly costs per person, which were doubled among not well-
controlled asthma patients compared with well-controlled
patients (£6592 vs. £3220). Projected yearly costs for the 2011
UK adult population treated with ICS+LABA were almost four
times higher for the not well-controlled group (£4877 million vs.
£1295 million). The total combined cost to society was estimated
at £6172 million per year, where direct costs amount to £1307
million and indirect costs to £4865 million.
DISCUSSION
Main ﬁndings
The current study sought to quantify the burden of poorly
controlled asthma through an evaluation of the prevalence and
correlates of uncontrolled asthma among a representative sample
of the UK adult population, focusing speciﬁcally on patients
currently being treated with ICS+LABA. Typically, these patients
with moderate to severe asthma may not be adequately
controlled with ICS and are prescribed ICS+LABA as maintenance
therapy alongside as-needed short-acting β2-agonists, and their
dosage is tuned depending on asthma control.2 In the current
study, over 60% of adult patients treated with ICS+LABA reported
poorly controlled asthma. Importantly, poor asthma control was
associated with a host of negative outcomes—including impaired
HRQoL, greater use of healthcare resources and greater work and
activity impairment—and substantial direct and indirect costs to
Table 2. Comparison of asthma respondents with well-controlled and
not well-controlled asthma treated with ICS+LABA without concurrent
diagnosis of COPD, chronic bronchitis, or emphysema: health
outcomes
ICS+LABA (free and ﬁxed-dose combination)
No COPD diagnosis Not well-
controlled
Well-
controlled
Total Test
n Mean n Mean n Mean P
Quality of life (SF-12v2)
Mental component score 452 43.0 249 47.4 701 44.6 <0.001
Physical component score 452 39.9 249 48.1 701 42.8 <0.001
Health utility 452 0.65 249 0.74 701 0.69 <0.001
Work productivity and activity impairment
Employed only
Absenteeism (%) 175 9.2 126 6.8 301 8.2 0.394
Presenteeism (%) 165 23.2 119 11.0 284 18.1 <0.001
Overall work impairment (%) 175 29.2 126 16.8 301 24.0 <0.001
Employed + unemployed
Activity impairment (%) 452 46.2 249 24.2 701 38.4 <0.001
Use of healthcare resources (not limited to asthma), past 6 months
Visited a physician (n, %) 0.053
GP 62 13.7% 35 14.1% 97 13.8%
Specialist 369 81.6% 191 76.7% 560 79.9%
None of the above 21 4.7% 23 9.2% 44 6.3%
A&E department visits (n, %) 0.016
No 355 78.5% 214 85.9% 569 81.2%
Yes 97 21.5% 35 14.1% 132 18.8%
Hospitalisations (n, %) 0.022
No 394 87.2% 231 92.8% 625 89.2%
Yes 58 12.8% 18 7.2% 76 10.8%
Number of GP visits 452 3.6 249 2.3 701 3.1 <0.001
Number of specialist visits 452 4.1 249 2.8 701 3.6 0.002
Number of A&E department
visits
452 0.13 249 0.07 701 0.11 0.022
Number of hospitalisations 452 0.22 249 0.14 701 0.19 0.016
Sample size 452 249 701
A&E accident & emergency, COPD chronic obstructive pulmonary disease,
GP general practitioner, ICS inhaled corticosteroids, LABA long-acting β2-
agonist, SF-12v2; Medical outcomes study 12-item short form survey
instrument
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society, estimated to be over £6000 million per year (over £1300
million and £4800 million, respectively).
While the primary goals of this study were not focused on
assessing adherence, participants’ responses suggested that a
signiﬁcant number of these patients stop taking their medication
when they feel better. This requires further investigation, but may
point at the need for more detailed patient education, self-
management plans and clariﬁcation around the importance of
medication adherence.
Interpretation of ﬁndings in relation to previously published work
Comparable to our ﬁndings, which showed that over 60% of adult
patients treated with ICS+LABA reported poorly controlled
asthma, previous population-based studies have also found that
only a minority of patients report being symptom free, with a
similar proportion of individuals as in the current study reporting
moderate or poor asthma control.21, 26, 27 A structured review of
24 patient surveys conducted in Europe and North America found
that patients tolerate poor symptom control, often understate
their symptoms, have low expectations of therapy, are unaware of
correct drug usage and demonstrate poor adherence to therapy.28
Similarly, the REcognise Asthma and LInk to Symptoms and
Experience (REALISE) survey conducted in 11 European countries,
including UK, found that despite experiencing symptoms and
exacerbations, many patients regard their asthma to be con-
trolled.14 Moreover, inaccurate assessment of disease severity can
result from an inadequate understanding of disease aetiology and
poor communication with patients by healthcare providers
(HCPs).28 In a practice audit for primary care physicians, controlled
asthma was positively associated with male sex, age < 35 years
and non-smoking or ex-smoking status.27 Importantly, and in
contrast to previous research,29 the current study showed no
signiﬁcant difference in adherence rates between patients with
well-controlled and not well-controlled asthma. We acknowledge
that assessing adherence using MMAS may overestimate adher-
ence and have poor precision and that this may account for the
lack of signiﬁcant differences between the groups. However,
despite these caveats, adherence seemed to be affected by
gender, age and income. While males had a lower likelihood of
being non-adherent, being older and having a higher income
were associated with a higher likelihood of being non-adherent.
These ﬁndings together suggest that poor asthma control is a
result of various factors and improving patients’ understanding
and communication with HCPs is important for accurate
assessment.
Table 3. Comparison of asthma respondents with well-controlled and not well-controlled asthma treated with ICS+LABA without concurrent
diagnosis of COPD, chronic bronchitis, or emphysema: asthma characteristics
ICS+LABA (free and ﬁxed-dose combination)
No COPD diagnosis Not well-
controlled
Well-controlled Total Test
n Index n Index n Index P
Length of diagnosis (years) 0.432
n, mean 450 22.5 247 21.6 697 22.2
ACT score <0.001
n, mean 452 15.3 249 22.8 701 17.9
Asthma control, past 4 weeks <0.001
n, mean 452 3.4 249 4.5 701 3.8
Talked to doctor about their asthma, past 12 months <0.001
n, mean 450 2.7 247 1.3 697 2.2
Frequency of asthma problems <0.001
Daily 189 41.8% 37 14.9% 226 32.2%
4–6 times a week 72 15.9% 10 4.0% 82 11.7%
2–3 times a week 97 21.5% 28 11.2% 125 17.8%
Once a week 28 6.2% 25 10.0% 53 7.6%
2–3 times a month 38 8.4% 41 16.5% 79 11.3%
Once a month or less often 28 6.2% 108 43.4% 136 19.4%
Self-reported asthma severity when taking medication <0.001
Mild intermittent 187 41.4% 212 85.1% 399 56.9%
Mild persistent 168 37.2% 30 12.1% 198 28.3%
Moderate persistent 90 19.9% 7 2.8% 97 13.8%
Severe persistent 7 1.6% 0 0.0% 7 1.0%
Self-reported asthma severity when not taking medication <0.001
Mild intermittent 21 4.7% 50 20.1% 71 10.1%
Mild persistent 74 16.4% 82 32.9% 156 22.3%
Moderate persistent 180 39.8% 75 30.1% 255 36.4%
Severe persistent 177 39.2% 42 16.9% 219 31.2%
Sample size 452 249 701
ACT asthma control test™, COPD chronic obstructive pulmonary disease, GP general practitioner, ICS inhaled corticosteroids, LABA long-acting β2-agonist
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Results of several studies indicate that poor asthma control is
associated with decreased quality of life and work productivity
and increased healthcare utilisation and costs.27–35 Consistent
with the results of the current study, results from a cross-sectional
study involving 15,149 patients showed that patients with
uncontrolled asthma had signiﬁcantly lower HRQoL as indicated
by the Marks Asthma Quality of Life Questionnaire and Paediatric
Asthma Caregivers Quality of Life Questionnaire.30 Similar results
were reported from 2006, 2008 and 2010 European NHWS and
2006 and 2011 US NHWS studies wherein uncontrolled asthma
was negatively correlated with patients’ HRQoL assessed by SF-8
and SF-12.22, 23, 31, 32 Moreover, uncontrolled asthma had a
negative impact on work productivity and activity.
The results of the current study are in agreement with results of
previous European NHWS and another US-based survey that
reported loss of work productivity and increased use of healthcare
resources associated with poor asthma control.22, 23, 33 In the
present study, healthcare resource utilisation, such as the number
of visits to GP, specialist, A&E and hospital, was signiﬁcantly higher
among patients with poorly controlled asthma and increased with
comorbidities. An online survey in 11 European countries
including 8000 patients found that 23.9% of patients reported
visiting an emergency department and 11.7% were hospitalised
overnight.14 Similarly, a prospective cohort online survey con-
ducted in the US showed a 3-fold greater risk of an asthma-related
doctor visit and a 10-fold greater risk of an emergency department
visit for asthma in adults with poorly controlled asthma.34 Work
and activity impairment and greater healthcare utilisation subse-
quently result in higher medical expenditures. In this study, yearly
costs per person were doubled among not well-controlled asthma
patients. Such increase in costs due to uncontrolled asthma has
also been reported previously.35
Strengths and limitations of this study
A strength of this study is that we analysed a combined sample
population of 2 years from the UK NHWS. The NHWS is a large
dataset and provides breadth and depth of rigorous patient-
reported data with national projections.36 It comprises data on the
utilisation of healthcare resources and patient-reported outcomes,
as well as patient attitudes and approaches to healthcare. This
study was therefore able to present comprehensive evidence on
work productivity and patient quality of life in patients with
asthma.
It is important to consider the results of the current study in the
context of the limitations present. An online, panel-based survey
has inherent limitations. This was a cross-sectional analysis and
therefore causal inferences cannot be drawn between predictor
and outcome variables. In addition, although analyses were
planned a priori and based on the existing literature, if more
stringent criteria for multiple analyses were applied, some of the
reported pairwise comparisons may become non-signiﬁcant.
However, given the paucity of research in this domain, these
results remain important in guiding future research. The data
examined in this study were self-reported and may thus have
been susceptible to recall errors. Further, responses to questions
were not veriﬁed with other sources, which may be particularly
notable regarding medical diagnoses as it was not possible to
conﬁrm them with health records. Finally, asthma-related health-
care utilisation has marked seasonal differences so our derivation
Table 4. Comparison of asthma respondents with well-controlled and not well-controlled asthma treated with ICS+LABA without concurrent
diagnosis of COPD, chronic bronchitis, or emphysema: adherence
ICS+LABA (free and ﬁxed-dose combination)
No COPD diagnosis Not well-
controlled
Well-controlled Total Test
n Index n Index n Index P
Adherence score (MMAS-4) 0.147
n, mean 452 0.94 249 0.81 701 0.89
Adherence level (MMAS-4) 0.361
High 224 49.6% 137 55.0% 361 51.5%
Medium 169 37.4% 85 34.1% 254 36.2%
Low 59 13.1% 27 10.8% 86 12.3%
Adherence questions
Do you ever forget to take your medicine? 0.717
No 293 64.8% 158 63.5% 451 64.3%
Yes 159 35.2% 91 36.6% 250 35.7%
Are you careless at times about taking your medicine? 0.406
No 349 77.2% 199 79.9% 548 78.2%
Yes 103 22.8% 50 20.1% 153 21.8%
When you feel better, do you sometimes stop taking your medicine? 0.016
No 330 73.0% 202 81.1% 532 75.9%
Yes 122 27.0% 47 18.9% 169 24.1%
Sometimes if you feel worse when you take the medicine, do you stop taking it? 0.104
No 411 90.9% 235 94.4% 646 92.2%
Yes 41 9.1% 14 5.6% 55 7.9%
Sample size 452 249 701
COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroids, LABA long-acting β2-agonist, MMAS-4, four-item Morisky medication adherence scale
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of annual rates from 6-month data may result in some imprecision
in our estimation of costs.
Although recruitment for the NHWS is designed to ensure
representativeness of the UK adult population, the panels from
which the sample was drawn may not be truly representative (e.g.,
over-representation of patients who are younger and in relatively
good health) and self-selection of respondents to complete the
survey upon being invited may have resulted in a sample of
patients whose characteristics differ from those of non-
participating respondents (e.g., greater motivation and ability to
participate In addition, although a combined sample population of
2 years from the UK NHWS was used, the number of patients
analysed was low for some of the subgroup analyses.
Finally, several analyses, while signiﬁcant, explained a relatively
low portion of the overall variance. This suggests that other factors
not considered in the current analysis may correlate with the
outcome variables, thus reiterating the need for further research.
Implications for future research, policy and practice
The results of this study, the ﬁrst of its kind in the UK, emphasise
the unmet medical need of patients with asthma who remain
symptomatic despite receiving combination therapy with
ICS+LABA. Importantly, the costs of this unmet medical need in
the UK have been fully quantiﬁed for the ﬁrst time. These
estimates are likely to be relevant to areas outside the UK;
therefore, these ﬁndings will be of interest to the international
community. Moreover, it is our opinion that the reported numbers
in terms of patients with uncontrolled asthma and yearly costs are
of relevance for inclusion in treatment guidelines.
CONCLUSIONS
The current study of UK adult patients with asthma found high
rates of poorly controlled disease among respondents. Critically,
poor control was associated with impairments across a number of
important health outcomes, thus further emphasising the
signiﬁcant burden associated with this medical condition. Further
research is needed in order to address the burden of persistent
uncontrolled asthma in patients treated with ICS+LABA, as well as
contribute to efforts to enhance treatment protocols and improve
national asthma management.
METHODS
Direct and indirect costs related to poor asthma control in adult patients
treated with ICS+LABA (i.e., ICS and LABA in free or ﬁxed-dose
combination) in the UK were estimated as follows: ﬁrst, the size of the
UK adult population taking ICS+LABA was estimated; then, direct costs
were estimated by multiplying unit costs by the number of physician visits,
hospitalisations and A&E department visits; ﬁnally, indirect costs were
calculated by applying wage statistics to the work impairment attributed
to health problems in employed patients (absenteeism and presenteeism).
HRQoL, activity impairment and adherence to asthma prescription
medication were also measured, in order to obtain a comprehensive
description of the burden associated with poor asthma control among
these patients.
Data source
This study employed a combined sample from the 2010 and 2011 UK
NHWS.36 The NHWS is a nationally representative online survey of
respondents aged 18 years or older conducted by Kantar Health, which
gathers data to provide timely patient-reported information on over 160
health conditions, including asthma. This study is part of the European
NHWS, which collects data from France, Germany, Italy, Spain and the UK;
each nation has the authority to publish country speciﬁc data. Data are
collected approximately every 18 months in Europe and every 12 months
in the United States (US). Before each periodic launch, NHWS gets
approved by a US-based Institutional review board (IRB), which in 2010 and
2011 was Essex IRB (Lebanon, NJ).
A random sample within a web-based panel, stratiﬁed by gender and
age, was included to represent the demographic composition of the UK
adult population. The survey sample was recruited from the general
population using a web-based consumer panel maintained by Lightspeed
GMI.37 The consumer panel recruits its panel members through opt-in
emails, co-registration with panel partners, e-newsletter campaigns,
banner placements and internal and external afﬁliate networks. All
panellists must explicitly agree to be a panel member, register with the
panel through a unique e-mail address and complete an in-depth
demographic registration proﬁle. These proﬁles are used to randomly
sample panel members for a survey in order to ensure a representative
sample. All respondents took part voluntarily and provided informed
consent. For the combined 2010–2011 NHWS, 148,171 invitations to
participate were sent in the UK; 49,485 potential participants responded;
45,899 were eligible to participate; 5494 were excluded because the
quotas for age and gender were reached and 30,065 completed the
survey. Further details on panel data management can be found at www.
lightspeedgmi.com/global-panels.
Sample
All respondents from the 2010 and 2011 UK NHWS who self-reported a
physician diagnosis of asthma and taking either a ﬁxed-dose or free
combination of ICS and LABA for their asthma were included in the
analysis. Patients reporting a concomitant physician diagnosis of COPD,
chronic bronchitis, or emphysema were excluded. This approach provided
a combined sample of more than 500 patients, with approximately half
being employed, and allowed for an adequate population size to provide
meaningful results. A multivariate analysis was used to adjust for
confounders. Sample size calculation was not performed as the primary
objective of this study was descriptive.
Measures
Demographics and health characteristics. Several demographic and health
characteristic variables were included for description of the study
population as well as for consideration as covariates in multivariable
models assessing the effect of asthma control on outcomes. These
variables included self-reported physician diagnosis of asthma; age;
gender; marital status; education; income; employment type; health
insurance; body mass index and asthma characteristics such as duration
of time with diagnosis, type of diagnosing and prescribing doctor,
frequency of asthma conversations with doctor, self-reported severity with
and without prescribed asthma medication, frequency of asthma
problems, seasonal variation of asthma problems and currently prescribed
asthma medications.
Table 5. Cost analysis: adjusted means and projections to the 2011
adult population of UK treated with ICS+LABA
Yearly costs Not well-controlled Well-controlled
£ per
person
Weighted
total (m)
£ per
person
Weighted
total (m)
Physician visits 551 408 m 375 151 m
A&E department visits 95 71 m 60 24 m
Hospitalisations 708 524 m 322 130 m
Direct costs 1355 1002 m 758 305 m
Absenteeism 2747 2032 m 1012 407 m
Presenteeism 4480 3314 m 2181 877 m
Indirect costs (overall
work impairment)
5238 3874 m 2463 991 m
Total costs 6592 4877 m 3220 1295 m
A&E accident & emergency, ICS inhaled corticosteroids, LABA long-acting
β2-agonist, m million
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Comorbidities. An adjusted CCI ref. 38 was calculated by weighting the
presence of HIV/AIDS, metastatic tumour, lymphoma, leukaemia, any
tumour, moderate or severe renal disease, hemiplegia, diabetes, mild liver
disease, ulcer disease, connective tissue disease, chronic pulmonary
disease, dementia, cerebrovascular disease, peripheral vascular disease,
myocardial infarction and congestive heart failure. The original CCI predicts
the likelihood of mortality. In the current study, the CCI was used to obtain
an estimate of comorbidity burden, wherein greater total index scores
indicate greater comorbidity burden on an individual.
Asthma control test™. ACT (QualityMetric Incorporated, Lincoln, RI, USA)
is a short, simple, self-reporting tool for identifying patients with poorly
controlled asthma.39 It measures the elements of asthma control as
deﬁned by the National Heart, Lung, and Blood Institute. ACT is an efﬁcient,
reliable and valid method for measuring asthma control.40 Scores range
from 5 to 25, with scores below 20 indicating poor asthma control.
Respondents for this study were assigned to the well-controlled group
when their ACT score was ≥20 and to the not well-controlled group when
their ACT score was <20.
Adherence. The MMAS refs. 41, 42 is a generic self-reported medication-
taking behaviour scale used for a wide variety of conditions including
asthma.43, 44 The MMAS-4 consists of four items with a scoring scheme of
‘Yes’ = 0 and ‘No’ = 1. The items are summed to give a range of scores from
low adherence to high adherence (0–4).39
Outcomes
Work productivity and activity impairment. Work productivity was
assessed using the WPAI questionnaire, a six-item validated instrument
which consists of four metrics: absenteeism (the percentage of work time
missed because of one’s health in the past 7 days), presenteeism (the
percentage of impairment experienced while at work in the past 7 days
because of one’s health), overall work productivity loss (an overall
impairment estimate that is a combination of absenteeism and
presenteeism) and activity impairment (the percentage of impairment in
daily activities because of one’s health in the past 7 days).45 Only
respondents who reported being full-time, part-time or self-employed
provided data for absenteeism, presenteeism and overall work impair-
ment. All respondents provided data for activity impairment.
Health-related quality of life. The revised Medical Outcomes Study SF-
12v2 Instrument is a multi-purpose, generic instrument comprising 12
questions.46 For the purpose of the present analysis, PCS and MCS scores
were included. These scores have a mean of 50 and a standard deviation of
10 for the US population. Health state utilities calculated using the short
form-6 dimensions algorithm were also included. Utility scores have
interval scoring properties and vary from 0 to 1.
Use of healthcare resources. Use of healthcare resources was deﬁned by
the reported number of visits to traditional healthcare providers (GP or
specialist), number of A&E visits and the number of hospitalisations in the
past 6 months. All of these variables were also dichotomised to ‘Yes’
(visited a traditional healthcare provider, A&E hospital visit and been
hospitalised) versus ‘No’.
Cost burden. Cost analysis was conducted at an individual patient level to
determine the healthcare costs (both direct and indirect) associated with
patients with well-controlled and not well-controlled asthma. To estimate
direct costs, the mean costs for an A&E visit, hospitalisation and physician
visit were selected. For each respondent, the number of each type of visit
was multiplied by 2 to project the annual number of visits and then
multiplied by its mean cost provided for 2011 by the National Health
Service Department of Health reference cost47 and Personal Social Services
Research Unit.48 Indirect costs were estimated by using annual wage
ﬁgures for 2011 provided by the Ofﬁce for National Statistics.49 Overall
work impairment (from the WPAI questionnaire), which represents the
total work time missed or impaired because of either absenteeism or
presenteeism, was multiplied by the median wage ﬁgure to estimate
annual indirect costs.
Analyses
First, descriptive analysis was used to characterise the population of
interest. The 2010–2011 combined NHWS UK sample was projected to the
2011 UK adult population using weights calculated according to UK age
and gender data as reﬂected in the US census international database.50
Bivariate analyses were then conducted to test whether there were
differences between well- and not well-controlled asthma respondents
currently taking ICS+LABA asthma medication regarding demographic
variables, general health characteristics and disease variables. Differences
between categorical variables were examined using Pearson’s chi-square
tests, and differences between continuous variables were examined using
t-tests. All the comparisons were planned a priori, and all variables
signiﬁcantly different at the 0.05 level were included in the multivariate
analyses. Smoking status, age, gender and length of diagnosis were
included, regardless of signiﬁcance, because of their theoretical relevance.
The aim of the multivariate analyses was to determine whether asthma
control in patients currently taking ICS+LABA was associated with
differences in health outcomes after controlling for potential confounders.
Generalised linear model regressions were used to test the association
between asthma control and components of HRQoL (MCS, PCS and health
utility), work productivity loss (absenteeism, presenteeism, overall work
impairment and activity impairment), healthcare resource use (number of
GP visits, specialist visits, hospitalisations and A&E visits) and adherence
(MMAS-4 score and response to each individual MMAS-4 question).
To estimate direct costs for cost analysis, the healthcare resource
utilisation models were re-run after multiplying the number of visits by the
relative unit costs to obtain adjusted estimates. Indirect costs were
estimated by re-running the work productivity loss models after multi-
plying the annual wage ﬁgures by the WPAI work impairment measures to
obtain adjusted estimates. This method has been outlined in prior
research.51
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